Dr Divya Gupta

Consultant, Research in rare skin disorders

Research Area

Clinical and translational research in genodermatoses and rare skin disorders, particularly epidermolysis bullosa (EB), with related interests in the clinical phenotyping and molecular diagnosis of inherited dermatological conditions, genetic testing and interpretation, rare-disease registries, multidisciplinary care, and the evaluation of practical treatment approaches.

Research Highlights

✧

Contributed to the development of an EB Registry in India, with referrals from different parts of the country

✧

Co-authored an Indian cohort study describing clinical and allelic heterogeneity in dystrophic EB, adding data on the range of clinical presentations and genetic findings in Indian patients.

✧

Contributed to work describing EB simplex associated with PLEC mutations in Indian families

✧

Participated in the evaluation of a tele-dermatology model for EB, examining its contribution to patient outreach and access to care.

✧

Co-authored educational reviews on the principles of genetics, clinical evaluation, sequencing technologies and interpretation for dermatologists, with the aim of making genetic approaches more accessible to clinical practice.

Research Projects

1

2019-2024: Development of a registry for Epidermolysis Bullosa in India (Funded by EB Research Partnership, USA)

2

2020: Safety and efficacy of Losartan in Patients with Dystrophic Epidermolysis Bullosa (DEB): an open labelled controlled trial (Funded by Indian Association of Dermatologists, Venereologists & Leprologists)

3

2023: Gene expression profiling of Vitiligo vulgaris skin pre- and post-phototherapy – a pilot study (Funded by TheraCUES GeoMx DSP Grant, in collaboration with Nanostring Technologies)

4

2026-2028: Prevalence of auto-antibodies and their clinical correlation in epidermolysis bullosa (EB)- a cross-sectional study in an Indian cohort (Funded by Indian Association of Dermatologists, Venereologists & Leprologists)

5

2026-2028: A Split-Body, Open label, Randomized Controlled Trial to Evaluate the Efficacy and Cost-Effectiveness of Mepilex Border versus Velfix® -S as First-Layer Dressing in Indian Patients with Epidermolysis Bullosa (Funded by Rajiv Gandhi University of Health Sciences, Karnataka)

Highlighted Publications

1

Viswanath A, Gupta D, Srinivasa M, et al. Integration of a tele-dermatology model for Epidermolysis Bullosa improves patient outreach: a before and after observational study. Front Digit Health. 2026;8:1848667. Published 2026 Jun 26. doi:10.3389/fdgth.2026.1848667

2

Dutta A, Gupta D, Ajnabi J, Dam B, Shilpashree P and Jamora C. Spatial transcriptomic analysis of the immune landscape following NBUVB treatment of vitiligo skin. Clin Transl Immunol. 2026; 15: e70080. https://doi.org/10.1002/cti2.70080

3

Gupta D, Jayashankar C, Srinivas M, et al. Clinical and allelic heterogeneity in dystrophic epidermolysis bullosa- lessons from an Indian cohort. PLoS One. 2023;18(8):e0289558. Published 2023 Aug 9. doi:10.1371/journal.pone.0289558

4

Gupta D, Jose TG, Vishwanathan GB. Genetics for dermatologists. Part 1: Fundamental concepts of structure, function, and clinical application. Indian J Dermatol Venereol Leprol. 2025;91(5):603-614. doi:10.25259/IJDVL_243_2025

5

Gupta D, Jose TG, Vishwanathan GB. Genetics for dermatologists. Part 2: Clinical evaluation, sequencing technologies and interpretation. Indian J Dermatol Venereol Leprol. 2025;91(6):741-751. doi:10.25259/IJDVL_500_2024

Current Lab Members

Theory Courses Taught

  • Theory classes for MSc students on EB and genodermatoses

Scroll to Top